A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study Confirming the Efficacy and Safety of Genz-112638 in Patients With Gaucher Disease Type 1 (ENGAGE)
Latest Information Update: 14 Oct 2021
Price :
$35 *
At a glance
- Drugs Eliglustat (Primary)
- Indications Gaucher's disease type I
- Focus Registrational; Therapeutic Use
- Acronyms ENGAGE
- Sponsors Genzyme Corporation; Sanofi Genzyme
- 01 Sep 2021 Results assessing final safety and efficacy outcomes for patients in the ENGAGE trial, published in the American Journal of Hematology
- 04 Dec 2018 Results analyzing bone mineral density T- and Z-scores and occurrence of bone pain and bone crises in 4 clinical trials (NCT00358150, NCT00891202, NCT00943111, and NCT01074944) presented at the 60th Annual Meeting and Exposition of the American Society of Hematology
- 04 Dec 2018 Results presented at the 60th Annual Meeting and Exposition of the American Society of Hematology